{"title":"影响牙科焦虑患者咪达唑仑静脉镇静剂量的因素:一项回顾性观察研究。","authors":"Hassan Abed","doi":"10.3290/j.ohpd.c_2226","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to assess factors that impact midazolam dose for intravenous sedation (IVS) in dental patients with anxiety.</p><p><strong>Materials and methods: </strong>This was a retrospective, observational study for adult, anxious patients (moderate to severe dental anxiety) who had different types of dental procedures under IVS with midazolam and local anaesthesia. A logbook of dental patients who had dental procedures was used to collect data on an Excel sheet (Microsoft Excel Workbook 2024).</p><p><strong>Results: </strong>Data of 233 patients were recorded. The average dose of IVS with midazolam delivered was 6.62 mg (SD = 3.24). Multivariable logistic regression found that two variables were statistically significant predictors for the IVS with midazolam dose, which are age (B = 1.30, S.E = 0.47, Exp(B) = 3.68, 95% CI = 1.45-9.33, P = 0.006) and non-surgical periodontal therapy with root planing (B = 0.85, SE = 0.39, Exp(B) = 2.35, 95% CI = 1.08-5.12, P = 0.031).</p><p><strong>Conclusions: </strong>Younger patients and non-surgical periodontal therapy with root planing appear to be predictors for higher doses of IVS with midazolam. Other variables that were not predictors to affect IVS with midazolam dose, such as medical history, American Society of Anesthesiologists (ASA) classification, medications, and others, are crucial, and they should not be neglected when designing the treatment plan to deliver dental treatment under IVS with midazolam.</p>","PeriodicalId":19696,"journal":{"name":"Oral health & preventive dentistry","volume":"23 ","pages":"499-506"},"PeriodicalIF":1.4000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12412757/pdf/","citationCount":"0","resultStr":"{\"title\":\"Factors Influencing Midazolam Dose for Intravenous Sedation in Dental Patients With Anxiety: A Retrospective Observational Study.\",\"authors\":\"Hassan Abed\",\"doi\":\"10.3290/j.ohpd.c_2226\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This study aimed to assess factors that impact midazolam dose for intravenous sedation (IVS) in dental patients with anxiety.</p><p><strong>Materials and methods: </strong>This was a retrospective, observational study for adult, anxious patients (moderate to severe dental anxiety) who had different types of dental procedures under IVS with midazolam and local anaesthesia. A logbook of dental patients who had dental procedures was used to collect data on an Excel sheet (Microsoft Excel Workbook 2024).</p><p><strong>Results: </strong>Data of 233 patients were recorded. The average dose of IVS with midazolam delivered was 6.62 mg (SD = 3.24). Multivariable logistic regression found that two variables were statistically significant predictors for the IVS with midazolam dose, which are age (B = 1.30, S.E = 0.47, Exp(B) = 3.68, 95% CI = 1.45-9.33, P = 0.006) and non-surgical periodontal therapy with root planing (B = 0.85, SE = 0.39, Exp(B) = 2.35, 95% CI = 1.08-5.12, P = 0.031).</p><p><strong>Conclusions: </strong>Younger patients and non-surgical periodontal therapy with root planing appear to be predictors for higher doses of IVS with midazolam. Other variables that were not predictors to affect IVS with midazolam dose, such as medical history, American Society of Anesthesiologists (ASA) classification, medications, and others, are crucial, and they should not be neglected when designing the treatment plan to deliver dental treatment under IVS with midazolam.</p>\",\"PeriodicalId\":19696,\"journal\":{\"name\":\"Oral health & preventive dentistry\",\"volume\":\"23 \",\"pages\":\"499-506\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-08-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12412757/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral health & preventive dentistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3290/j.ohpd.c_2226\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DENTISTRY, ORAL SURGERY & MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral health & preventive dentistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3290/j.ohpd.c_2226","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
引用次数: 0
摘要
目的:本研究旨在评估影响咪达唑仑静脉镇静(IVS)剂量的因素。材料和方法:这是一项回顾性观察性研究,对象是在静脉注射下使用咪达唑仑和局部麻醉进行不同类型牙科手术的成年焦虑患者(中度至重度牙科焦虑)。在Excel表格(Microsoft Excel Workbook 2024)中使用了牙科手术患者的日志来收集数据。结果:记录了233例患者的资料。平均给药剂量为6.62 mg (SD = 3.24)。多变量logistic回归分析发现,年龄(B = 1.30,标准差= 0.47,Exp(B) = 3.68, 95% CI = 1.45 ~ 9.33, P = 0.006)和牙周非手术刨根治疗(B = 0.85, SE = 0.39, Exp(B) = 2.35, 95% CI = 1.08 ~ 5.12, P = 0.031)是咪达唑仑剂量IVS的显著预测因子。结论:年轻患者和非手术牙周治疗伴牙根刨平似乎是高剂量静脉注射咪达唑仑的预测因素。其他不影响咪达唑仑剂量IVS的变量,如病史、美国麻醉医师协会(ASA)分类、药物等,都是至关重要的,在设计咪达唑仑IVS牙科治疗方案时,不应忽视这些变量。
Factors Influencing Midazolam Dose for Intravenous Sedation in Dental Patients With Anxiety: A Retrospective Observational Study.
Purpose: This study aimed to assess factors that impact midazolam dose for intravenous sedation (IVS) in dental patients with anxiety.
Materials and methods: This was a retrospective, observational study for adult, anxious patients (moderate to severe dental anxiety) who had different types of dental procedures under IVS with midazolam and local anaesthesia. A logbook of dental patients who had dental procedures was used to collect data on an Excel sheet (Microsoft Excel Workbook 2024).
Results: Data of 233 patients were recorded. The average dose of IVS with midazolam delivered was 6.62 mg (SD = 3.24). Multivariable logistic regression found that two variables were statistically significant predictors for the IVS with midazolam dose, which are age (B = 1.30, S.E = 0.47, Exp(B) = 3.68, 95% CI = 1.45-9.33, P = 0.006) and non-surgical periodontal therapy with root planing (B = 0.85, SE = 0.39, Exp(B) = 2.35, 95% CI = 1.08-5.12, P = 0.031).
Conclusions: Younger patients and non-surgical periodontal therapy with root planing appear to be predictors for higher doses of IVS with midazolam. Other variables that were not predictors to affect IVS with midazolam dose, such as medical history, American Society of Anesthesiologists (ASA) classification, medications, and others, are crucial, and they should not be neglected when designing the treatment plan to deliver dental treatment under IVS with midazolam.
期刊介绍:
Clinicians, general practitioners, teachers, researchers, and public health administrators will find this journal an indispensable source of essential, timely information about scientific progress in the fields of oral health and the prevention of caries, periodontal diseases, oral mucosal diseases, and dental trauma. Central topics, including oral hygiene, oral epidemiology, oral health promotion, and public health issues, are covered in peer-reviewed articles such as clinical and basic science research reports; reviews; invited focus articles, commentaries, and guest editorials; and symposium, workshop, and conference proceedings.